MedTrace Logo

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

NCT05781360 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2024-12-20

No results posted yet for this study

Summary

This is a multicenter, open-label, phase I study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of SIM0237 in participants with advanced solid tumors.

Conditions

  • Locally Advanced Unresectable or Metastatic Solid Tumor

Interventions

DRUG

SIM0237

SIM0237 should be administered intravenously at recommended dose qw or other dosing regimens

Sponsors & Collaborators

  • Shanghai Xianxiang Medical Technology Co., Ltd.

    collaborator INDUSTRY

  • Simcere Zaiming

    collaborator UNKNOWN

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Bijoyesh Mookerjee, MD · Simcere Zaiming

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-08
Primary Completion
2024-05-25
Completion
2024-05-25
FDA Drug
Yes

Countries

  • United States
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05781360 on ClinicalTrials.gov